While Belviq lorcaserin and Qsymia phentermine/topiramate have a label indication in common, physicians scrutinizing the details may come to different conclusions about prescribing the obesity drugs.

This was made clear by two doctors contacted by BioCentury. Each plans to use Belviq and Qsymia for different subgroups of obese patients, but their opinions diverged on which drug is best for which subgroup.